{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:08:27Z","timestamp":1793207307441,"version":"4.5.0"},"reference-count":101,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.autrev.2021.102995","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T02:02:59Z","timestamp":1637028179000},"page":"102995","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":51,"title":["Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review"],"prefix":"10.1016","volume":"21","author":[{"given":"Elvis","family":"Hysa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Gotelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sammor\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Amedeo","family":"Cimmino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Paolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Pizzorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Sulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Cutolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.102995_bb0005","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrrheum.2012.97","article-title":"Clinical features of polymyalgia rheumatica and giant cell arteritis","volume":"8","author":"Salvarani","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102692","article-title":"Impact of age at diagnosis in polymyalgia rheumatica: a retrospective cohort study of 218 patients","volume":"19","author":"Van Hemelen","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0015","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/ken294","article-title":"Polymyalgia rheumatica vs late-onset rheumatoid arthritis","volume":"48","author":"Cutolo","year":"2008","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2021.102995_bb0020","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/s40266-019-00705-5","article-title":"Pathogenesis, diagnosis and management of polymyalgia rheumatica","volume":"36","author":"Camellino","year":"2019","journal-title":"Drugs Aging"},{"key":"10.1016\/j.autrev.2021.102995_bb0025","doi-asserted-by":"crossref","first-page":"564","DOI":"10.55563\/clinexprheumatol\/vn1qbp","article-title":"Seasonal onset of polymyalgia rheumatica: correlations with the pattern of clinical presentation, disease severity and outcome in 383 patients from a single centre","volume":"39","author":"Sobrero","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0030","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1016\/j.semarthrit.2020.05.023","article-title":"A seasonal pattern in the onset of polymyalgia rheumatica and giant cell arteritis? A systematic review and meta-analysis","volume":"50","author":"Hysa","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0040","article-title":"Epidemiology of major relapse in giant cell arteritis: a study-level meta-analysis","author":"Aussedat","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0045","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4081\/reumatismo.2020.1291","article-title":"Management of giant cell arteritis among general practitioners from Genoa, Italy: a web-based survey","volume":"72","author":"Clini","year":"2021","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2021.102995_bb0050","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.autrev.2017.11.029","article-title":"Large-vessel involvement and aortic dilation in giant-cell arteritis. A multicenter study of 549 patients","volume":"17","author":"de Boysson","year":"2018","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0055","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4081\/reumatismo.2018.1048","article-title":"Pathogenesis of polymyalgia rheumatica","volume":"70","author":"Guggino","year":"2018","journal-title":"Reumatismo"},{"key":"10.1016\/j.autrev.2021.102995_bb0060","article-title":"The pathophysiology of polymyalgia rheumatica, small pieces of a big puzzle","volume":"19","author":"Carvajal","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0030297","article-title":"A proposed classification of the immunological diseases","volume":"3","author":"McGonagle","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.autrev.2021.102995_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000694","article-title":"Polymyalgia rheumatica: an autoinflammatory disorder?","volume":"4","author":"Floris","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2021.102995_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102774","article-title":"Systemic autoinflammatory disease in adults","volume":"20","author":"Betrains","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102743","article-title":"An updated advance of autoantibodies in autoimmune diseases","volume":"20","author":"Xiao","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0085","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj"},{"key":"10.1016\/j.autrev.2021.102995_bb0090","doi-asserted-by":"crossref","first-page":"580","DOI":"10.5195\/jmla.2018.513","article-title":"Covidence and Rayyan","volume":"106","author":"Kellermeyer","year":"2018","journal-title":"J Med Libr Assoc"},{"key":"10.1016\/j.autrev.2021.102995_bb0095","doi-asserted-by":"crossref","first-page":"5.1.1","DOI":"10.1002\/cpim.40","article-title":"Flow cytometry: an overview","volume":"120","author":"McKinnon","year":"2018","journal-title":"Curr Protoc Immunol"},{"key":"10.1016\/j.autrev.2021.102995_bb0100","series-title":"ANCA-associated vasculitides: immunological and clinical aspects","first-page":"363","article-title":"Anti-neutrophil cytoplasmic antibodies in giant cell arteritis and polymyalgia rheumatica","author":"Cats","year":"1993"},{"key":"10.1016\/j.autrev.2021.102995_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2021.102684","article-title":"Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in giant cell arteritis and polymyalgia rheumatica","volume":"123","author":"Graver","year":"2021","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.102995_bb0110","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3109\/03009749509095150","article-title":"Clinical value of measuring soluble interleukin-2 receptor in polymyalgia rheumatica","volume":"24","author":"Gripenberg","year":"1995","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0115","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1002\/art.23924","article-title":"Serum interleukin-6 receptor in polymyalgia rheumatica: a potential marker of relapse\/recurrence risk","volume":"59","author":"Pulsatelli","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0120","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1136\/ard.2010.140194","article-title":"Expression and function of toll-like receptors in peripheral blood mononuclear cells of patients with polymyalgia rheumatica and giant cell arteritis","volume":"70","author":"\u00c1lvarez","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0125","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1042\/CS20180415","article-title":"Identification of an activated neutrophil phenotype in polymyalgia rheumatica during steroid treatment: a potential involvement of immune cell cross-talk","volume":"133","author":"Nadkarni","year":"2019","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.autrev.2021.102995_bb0130","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1093\/rheumatology\/keaa054","article-title":"Association of mucosal-associated invariant T cells with different disease phases of polymyalgia rheumatica","volume":"59","author":"Nakajima","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102995_bb0135","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/art.1780360913","article-title":"Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis","volume":"36","author":"Roche","year":"1993","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0140","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3389\/fimmu.2019.01981","article-title":"Leukocyte dynamics reveal a persistent myeloid dominance in giant cell arteritis and polymyalgia rheumatica","volume":"10","author":"van Sleen","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2021.102995_bb0145","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1189\/jlb.0113034","article-title":"Phagocyte dysfunction in polymyalgia rheumatica and other age-related, chronic, inflammatory conditions","volume":"94","author":"\u00c1lvarez-Rodr\u00edguez","year":"2013","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2021.102995_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23000","article-title":"Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are associated with disease activity in polymyalgia rheumatica","volume":"33","author":"Jung","year":"2019","journal-title":"J Clin Lab Anal"},{"key":"10.1016\/j.autrev.2021.102995_bb0155","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/rheumatology\/kex169","article-title":"Correction of abnormal B-cell subset distribution by interleukin-6 receptor blockade in polymyalgia rheumatica","volume":"56","author":"Carvajal","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102995_bb0160","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.autrev.2017.07.008","article-title":"Endothelial cells: from innocent bystanders to active participants in immune responses","volume":"16","author":"Al-Soudi","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0165","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/j.1365-2796.2011.02510.x","article-title":"Imbalance between endothelial injury and repair in patients with polymyalgia rheumatica: improvement with corticosteroid treatment","volume":"272","author":"Pirro","year":"2012","journal-title":"J Intern Med"},{"key":"10.1016\/j.autrev.2021.102995_bb0170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s00296-009-0949-9","article-title":"Altered T-cell subtypes in spondyloarthritis, rheumatoid arthritis and polymyalgia rheumatica","volume":"30","author":"Dejaco","year":"2010","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.autrev.2021.102995_bb0175","first-page":"1079","article-title":"Analysis of peripheral blood lymphocytes using flow cytometry in polymyalgia rheumatica, RS3PE and early rheumatoid arthritis","volume":"26","author":"Shimojima","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0180","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/art.34647","article-title":"Th1 and Th17 lymphocytes expressing CD161 are implicated in giant cell arteritis and polymyalgia rheumatica pathogenesis","volume":"64","author":"Samson","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0185","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1136\/annrheumdis-2012-201660","article-title":"NKG2D stimulated T-cell autoreactivity in giant cell arteritis and polymyalgia rheumatica","volume":"72","author":"Dejaco","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0190","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/ard.2003.005900","article-title":"Selective T cell receptor decrease in peripheral blood T lymphocytes of patients with polymyalgia rheumatica and giant cell arteritis","volume":"63","author":"Lopez-Hoyos","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0195","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1002\/art.38625","article-title":"Disturbed B cell homeostasis in newly diagnosed giant cell arteritis and polymyalgia rheumatica","volume":"66","author":"van der Geest","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0200","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/ard.2006.051979","article-title":"Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis","volume":"65","author":"Cutolo","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0205","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1093\/rheumatology\/keu526","article-title":"Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica","volume":"54","author":"van der Geest","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102995_bb0210","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1093\/rheumatology\/39.6.624","article-title":"The adrenal steroid status in relation to inflammatory cytokines (interleukin-6 and tumour necrosis factor) in polymyalgia rheumatica","volume":"39","author":"Straub","year":"2000","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102995_bb0215","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/ard.2008.103663","article-title":"Circulating cytokines in active polymyalgia rheumatica","volume":"69","author":"Alvarez-Rodr\u00edguez","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0220","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1093\/rheumatology\/29.6.456","article-title":"Interleukin-6 in serum of patients with polymyalgia rheumatica and giant cell arteritis","volume":"29","author":"Dasgupta","year":"1990","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0225","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/art.20901","article-title":"Acute-phase reactants and the risk of relapse\/recurrence in polymyalgia rheumatica: a prospective followup study","volume":"53","author":"Salvarani","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0230","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/ard.55.6.403-b","article-title":"Interleukin-6 in clinical relapses of polymyalgia rheumatica and giant cell arteritis","volume":"55","author":"Caplanne","year":"1996","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0235","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/rheumatology\/37.7.766","article-title":"Cytokines and adhesion molecules in patients with polymyalgia rheumatica","volume":"37","author":"Uddhammar","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0240","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1186\/s13075-016-1072-4","article-title":"Circadian variations in clinical symptoms and concentrations of inflammatory cytokines, melatonin, and cortisol in polymyalgia rheumatica before and during prednisolone treatment: a controlled, observational, clinical experimental study","volume":"18","author":"Galbo","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2021.102995_bb0245","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/rheumatology\/37.7.797","article-title":"Circulating levels of IL-1beta, IL-6 and soluble IL-2 receptor in polymyalgia rheumatica and giant cell arteritis and rheumatoid arthritis","volume":"37","author":"Pountain","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0250","first-page":"1865","article-title":"Serum soluble CD4 and CD8 levels in polymyalgia rheumatica","volume":"21","author":"Salvarani","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0255","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1136\/ard.54.8.640","article-title":"Role of peripheral CD8 lymphocytes and soluble IL-2 receptor in predicting the duration of corticosteroid treatment in polymyalgia rheumatica and giant cell arteritis","volume":"54","author":"Salvarani","year":"1995","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0260","first-page":"1318","article-title":"Favorable role of interleukin 10 in patients with polymyalgia rheumatica","volume":"26","author":"Straub","year":"1999","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0265","first-page":"263","article-title":"Elevated serum concentrations of the chemokine RANTES in patients with polymyalgia rheumatica","volume":"16","author":"Pulsatelli","year":"1998","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0270","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/ard.59.10.775","article-title":"Monocyte chemoattractant protein 1 (MCP-1) in temporal arteritis and polymyalgia rheumatica","volume":"59","author":"Ellingsen","year":"2000","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0275","first-page":"176","article-title":"High angiopoietin-2 levels associate with arterial inflammation and long-term glucocorticoid requirement in polymyalgia rheumatica","volume":"59","author":"van Sleen","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2021.102995_bb0280","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/1529-0131(200011)43:11<2472::AID-ANR14>3.0.CO;2-B","article-title":"Vascular endothelial growth factor production in polymyalgia rheumatica","volume":"43","author":"Meliconi","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0285","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1002\/art.1780390719","article-title":"Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment","volume":"39","author":"Meliconi","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0290","first-page":"562","article-title":"Synovial expression of vasoactive intestinal peptide in polymyalgia rheumatica","volume":"24","author":"Pulsatelli","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0295","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7326\/0003-4819-121-7-199410010-00003","article-title":"Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis","volume":"121","author":"Weyand","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2021.102995_bb0300","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/03009740802448841","article-title":"Expression of the class I interferon-related MxA protein in temporal arteries in polymyalgia rheumatica and temporal arteritis","volume":"38","author":"Nordborg","year":"2009","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0305","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1002\/art.27728","article-title":"Increased muscle interstitial levels of inflammatory cytokines in polymyalgia rheumatica","volume":"62","author":"Kreiner","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0310","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/ard.46.10.746","article-title":"Antibodies to intermediate filaments in polymyalgia rheumatica and giant cell arteritis: a sequential study","volume":"46","author":"Dasgupta","year":"1987","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0315","first-page":"429","article-title":"Anti-neutrophil cytoplasm antibodies in patients with giant cell arteritis and\/or polymyalgia rheumatica","volume":"143","author":"Berthelot","year":"1992","journal-title":"Ann Med Interne (Paris)"},{"key":"10.1016\/j.autrev.2021.102995_bb0320","first-page":"474","article-title":"Anticardiolipin antibodies in polymyalgia rheumatica-giant cell arteritis: association with severe vascular complications","volume":"90","author":"Espinoza","year":"1991","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2021.102995_bb0325","first-page":"1694","article-title":"A longitudinal study of anticardiolipin antibody in polymyalgia rheumatica and giant cell arteritis","volume":"22","author":"Chakravarty","year":"1995","journal-title":"J Rheumatol"},{"issue":"Suppl. 103","key":"10.1016\/j.autrev.2021.102995_bb0330","first-page":"94","article-title":"Serum immunoglobulin G4 in giant cell arteritis and polymyalgia rheumatica","volume":"35","author":"Burkel","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0335","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/annrheumdis-2011-200413","article-title":"Association of ferritin autoantibodies with giant cell arteritis\/polymyalgia rheumatica","volume":"71","author":"Baerlecken","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0340","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3109\/08916939508993340","article-title":"The relationship of anti-endothelial cell antibodies to anti-phospholipid antibodies in patients with giant cell arteritis and\/or polymyalgia rheumatica","volume":"20","author":"Le Tonqu\u00e8ze","year":"1995","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2021.102995_bb0345","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/rheumatology\/30.5.349","article-title":"Prevalence of hypothyroidism in patients with polymyalgia rheumatica and giant cell arteritis","volume":"30","author":"Bowness","year":"1991","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0350","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2249.2002.01751.x","article-title":"Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica","volume":"127","author":"Schmits","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.102995_bb0355","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11926-021-00980-5","article-title":"Blood biomarkers for monitoring and prognosis of large vessel vasculitides","volume":"23","author":"Tombetti","year":"2021","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2021.102995_bb0360","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.autrev.2009.01.012","article-title":"Interleukin-6 as a key player in systemic inflammation and joint destruction","volume":"8","author":"Fonseca","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0365","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.semarthrit.2019.12.005","article-title":"Tocilizumab in isolated polymyalgia rheumatica: a systematic literature review","volume":"50","author":"Akiyama","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2021.102995_bb0370","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-146-9-200705010-00005","article-title":"Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial","volume":"146","author":"Salvarani","year":"2007","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2021.102995_bb0375","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1136\/annrheumdis-2015-207578","volume":"74","author":"Dejaco","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0380","doi-asserted-by":"crossref","DOI":"10.1177\/20587384211006584","article-title":"Off-label use of anti-IL-1 drugs in rheumatic diseases","volume":"35","author":"Stefania","year":"2021","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.autrev.2021.102995_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102785","article-title":"The revisited role of interleukin-1 alpha and beta in autoimmune and inflammatory disorders and in comorbidities","volume":"20","author":"Galozzi","year":"2021","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0390","first-page":"321","article-title":"Sex differences in temporal arteritis and polymyalgia rheumatica","volume":"29","author":"Narvaez","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0395","first-page":"S9","article-title":"Epidemiology of polymyalgia rheumatica","volume":"18","author":"Cimmino","year":"2000","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0400","doi-asserted-by":"crossref","first-page":"366","DOI":"10.5414\/CP203901","article-title":"Methotrexate for treating polymyalgia rheumatica: a meta-analysis of randomized controlled trials","volume":"59","author":"Song","year":"2021","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.102995_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102421","article-title":"The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis","volume":"19","author":"Favalli","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102390","article-title":"JAK inhibitors for the treatment of autoimmune and inflammatory diseases","volume":"18","author":"Jamilloux","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0415","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/BOR.0b013e32835c7e32","article-title":"The interferon signature in autoimmune diseases","volume":"25","author":"R\u00f6nnblom","year":"2013","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0420","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1136\/annrheumdis-2017-212257","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102687","article-title":"Immune checkpoint inhibitors therapies in patients with cancer and preexisting autoimmune diseases: a meta-analysis of observational studies","volume":"19","author":"Xie","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0430","first-page":"E970","article-title":"Immunoinhibitory checkpoint deficiency in medium and large vessel vasculitis","volume":"114","author":"Zhang","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2021.102995_bb0435","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1189\/jlb.3MA0717-283","article-title":"The immunoinhibitory PD-1\/PD-L1 pathway in inflammatory blood vessel disease","volume":"103","author":"Weyand","year":"2018","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.autrev.2021.102995_bb0440","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.autrev.2021.102995_bb0445","article-title":"Identification and classification of polymyalgia rheumatica (PMR) and PMR-like syndromes following immune checkpoint inhibitors (ICIs) therapy: discussion points and grey areas emerging from a systematic review of published literature","volume":"7","author":"Manzo","year":"2020","journal-title":"Medicines (Basel)"},{"key":"10.1016\/j.autrev.2021.102995_bb0450","doi-asserted-by":"crossref","unstructured":"Marsman D.E., den Broeder N., van den Hoogen F.H.J., den Broeder A.A. and van der Maas A. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol., https:\/\/doi.org\/10.1016\/S2665-9913(21)00245-9.","DOI":"10.1016\/S2665-9913(21)00245-9"},{"key":"10.1016\/j.autrev.2021.102995_bb0455","first-page":"309","article-title":"Increased prevalence of antibodies to adenovirus and respiratory syncytial virus in polymyalgia rheumatica","volume":"11","author":"Cimmino","year":"1993","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0460","doi-asserted-by":"crossref","first-page":"444","DOI":"10.5114\/reum.2020.101580","article-title":"Liver involvement in polymyalgia rheumatica and giant cell arteritis","volume":"58","author":"Hysa","year":"2020","journal-title":"Reumatologia"},{"key":"10.1016\/j.autrev.2021.102995_bb0465","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1139\/O10-027","article-title":"Higher expression of ferritin protects Chlamydia trachomatis infected HeLa 229 cells from reactive oxygen species mediated cell death","volume":"88","author":"Vardhan","year":"2010","journal-title":"Biochem Cell Biol"},{"key":"10.1016\/j.autrev.2021.102995_bb0470","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1128\/IAI.00210-10","article-title":"Antibody targeting the ferritin-like protein controls Listeria infection","volume":"78","author":"Mohamed","year":"2010","journal-title":"Infect Immun"},{"key":"10.1016\/j.autrev.2021.102995_bb0475","first-page":"112","article-title":"Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection","volume":"23","author":"Elling","year":"1996","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2021.102995_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102614","article-title":"Microorganisms associated to thyroid autoimmunity","volume":"19","author":"Cuan-Baltazar","year":"2020","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.102995_bb0485","doi-asserted-by":"crossref","unstructured":"Duhaut P., Berruyer M., Pinede L., Demolombe-Rague S., Loire R., Seydoux D., et al. Anticardiolipin antibodies and giant cell arteritis: a prospective, multicenter case-control study. Groupe de Recherche sur l'Art\u00e9rite \u00e0 Cellules G\u00e9antes. Arthritis Rheum 1998; 41: 701\u20139. (10.1002\/1529-0131(199804)41:4<701::Aid-art18>3.0.Co;2-p).","DOI":"10.1002\/1529-0131(199804)41:4<701::AID-ART18>3.0.CO;2-P"},{"key":"10.1016\/j.autrev.2021.102995_bb0490","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/ard.62.5.388","article-title":"Antiphospholipid antibodies and infections","volume":"62","author":"Asherson","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0495","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/ard.43.2.264","article-title":"Polymyalgia rheumatica and antimitochondrial antibodies","volume":"43","author":"Sattar","year":"1984","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2021.102995_bb0500","first-page":"57","article-title":"Antimitochondrial antibodies and primary biliary cholangitis in patients with polymyalgia rheumatica\/giant cell arteritis","author":"Manzo","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.autrev.2021.102995_bb0505","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2020.102732","article-title":"Giant cell arteritis or polymyalgia rheumatica after influenza vaccination: a study of 12 patients and a literature review","volume":"20","author":"Liozon","year":"2021","journal-title":"Autoimmun Rev"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002755?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221002755?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:23:32Z","timestamp":1761600212000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221002755"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":101,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1568997221002755"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102995","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune system activation in polymyalgia rheumatica: Which balance between autoinflammation and autoimmunity? A systematic review","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.102995","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102995"}}